Drug
Dulaglutide
Dulaglutide: highest development phase Post-Market, developed by Eli Lilly. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dulaglutide NCT03315780 | Post-Market | Type 2 Diabetes |
| Dulaglutide NCT04809220 | Phase 3 | Diabetes Mellitus |
Latest
No recent events.
Follow Dulaglutide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.